Registry for patients with sarcoma and carcinosarcoma in Germany

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The GISAR registry aims to collect comprehensive data on patients diagnosed with sarcoma and carcinosarcoma treated in Germany. It employs an open and modular approach, allowing for both prospective and retrospective data collection to address specific scientific questions regarding treatment effectiveness and adverse effects. By including a diverse patient population, the registry seeks to illuminate the current treatment landscape and improve understanding of various sarcoma subtypes and their management. This initiative is crucial given the rarity and complexity of these tumors, which often require multimodal treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological verified bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity like giant cell tumors of the bone (GCTB), desmoid tumors, atypical lipomatous tumors etc. - independent of therapy form and therapy line - or Histological verified sarcomatoid carcinomas/ carcinosarcomas: tumors with histological, cytological, or molecular properties of both epithelial tumors ("carcinoma") and mesenchymal tumors ("sarcoma") - independent of therapy form and therapy line.
* Signed informed consent form or equivalent (s. chapter 10)
* Age ≥18 years

Exclusion Criteria:

* none

Where it's running

• Universitätsklinikum Tübingen
  Tübingen, Baden-Wurttemberg, Germany Recruiting
• Universitätsklinikum Erlangen
  Erlangen, Bavaria, Germany Recruiting
• HELIOS Klinikum Bad Saarow
  Bad Saarow, Germany Recruiting
• HELIOS Klinikum Berlin-Buch
  Berlin, Germany Recruiting
• Vivantes Klinikum Berlin-Spandau
  Berlin-Spandau, Germany Recruiting
• Universitätsklinikum Erlangen
  Erlangen, Germany Recruiting

Study contacts

• Study coordinator: Daniel Pink, Dr. med.
• Email: daniel.pink@helios-gesundheit.de
• Phone: +49 33631 7

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sequential CD146- and HER2-targeted CAR T-cell therapy for advanced sarcoma

  This treatment will test whether giving a patient's own CAR T cells that target CD146 and HER2, one after the other, can shrink tumors in children and adults with relapsed or refractory advanced sarcoma.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07066982

• Combining PARP inhibitors, immunotherapy, and targeted radiation for advanced sarcoma

  This study is testing a new treatment that combines two drugs and targeted radiation to see if it can help people with advanced bone and soft tissue sarcomas feel better and improve their outcomes.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06074692

• Preventing wound complications after limb sarcoma surgery with a single-use negative-pressure dressing

  This test will try a single-use negative-pressure wound dressing (PICO14) to see if it reduces wound complications after limb high-grade soft tissue sarcoma surgery in adults who received preoperative radiotherapy.

  Recruiting Istituto Oncologico Veneto IRCCS · Padova, Italy/Padova · NCT06941194

• Combining Retifanlimab with chemotherapy for advanced soft tissue sarcoma

  This study is testing if adding Retifanlimab to chemotherapy can help people with advanced soft tissue sarcoma fight their cancer better than the usual treatments.

  Recruiting Phase 1/2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT04577014

• Preventing heart problems in overweight/obese young sarcoma survivors with tirzepatide

  This feasibility study tests whether tirzepatide can be safely given to overweight or obese young adults (18–39) who have completed doxorubicin for soft tissue or bone sarcoma to see if it’s feasible to use in the first year after therapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07874828

• MIGHTY: CAR T cells targeting B7-H3 for pediatric, teen, and young adult sarcoma

  This Phase 1 trial tests autologous hBRCA84D CAR T cells in kids, teens, and young adults (1–24) with relapsed or refractory RMS, ES, or DSRCT to see if the therapy is feasible and safe.

  Recruiting at 2 sites Phase 1 University College, London · London and 1 other locations · NCT07751380

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.